Alliance Global Partners initiated coverage on CollPlant with a new price target
$CLGN
Industrial Specialties
Health Care
Alliance Global Partners initiated coverage of CollPlant with a rating of Buy and set a new price target of $22.75
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/17/2023 | $22.75 | Buy | Alliance Global Partners |
Bio-printing technology now enables fabrication of 200cc implant size and above to address future commercial demand Interim pre-clinical data shows tissue growth including regeneration of maturing connective tissue as well as neovascularization, synchronized with progressive implant degradation No adverse tissue reaction was observed Large-animal studies with commercial-size implants are currently underway with results expected in Q4 2024 and Q1 2025
HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates CollPlant Biotechnologies (NASDAQ:CLGN) with a Buy and maintains $11 price target.
CollPlant Biotechnologies (NASDAQ:CLGN) reported quarterly losses of $(0.35) per share which met the analyst consensus estimate. This is a 20.69 percent decrease over losses of $(0.29) per share from the same period last year. The company reported quarterly sales of $98.00 thousand which missed the analyst consensus estimate of $600.00 thousand by 83.67 percent. This is a 77.37 percent decrease over sales of $433.00 thousand the same period last year.
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
SC 13G/A - CollPlant Biotechnologies Ltd (0001631487) (Subject)
- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on November 27th at 10:00 a.m. Eastern Standard Time. Confere
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter
Conference call to be held on Tuesday, August 20, 2024, at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 6, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial statements for the second quarter of 2024 on Tuesday, August 20, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial statements and corporate updates on August 20 at 10:00 a.m. Eastern Daylight Time. Conference ca
- Conference call to be held on Wednesday, November 27, 2024 at 10:00 a.m. U.S. EST - REHOVOT, Israel, Nov. 12, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced that it will report financial results for the third quarter of 2024 on Wednesday, November 27, 2024, before the opening of the U.S. financial markets. The Company will then host a conference call and webcast to discuss its financial results and corporate updates on November 27th at 10:00 a.m. Eastern Standard Time. Confere
- Recently initiated a pre-clinical trial with CollPlant's rhCollagen-based regenerative breast implants, printed with Stratasys' Origin® 3D printer that are 200cc in volume - Breast implants could address a $3.0 billion market opportunity - Cash and cash equivalents balance as of June 30, 2024 was $18.9 million - Conference call to be held today at 10:00 a.m. U.S. EDT REHOVOT, Israel, Aug. 20, 2024 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter
3D Printed Breast implants consisting of 200cc in volume of CollPlant's rhCollagen-based bioinks produced on a Stratasys' Origin® printer to be tested Technology innovation addresses a $3.0 billion market opportunity Study to focus on ability of implants to grow natural breast tissue and completely degrade over time In a significant step in the advancement of regenerative medicine, CollPlant Biotechnologies (NASDAQ:CLGN) and Stratasys Ltd. (NASDAQ:SSYS) today announced the initiation of a pre-clinical study with 200cc commercial-sized regenerative implants printed on a Stratasys Origin® 3D printer. This press release features multimedia. View the full release here: https://www.busine
Alliance Global Partners initiated coverage of CollPlant with a rating of Buy and set a new price target of $22.75
HC Wainwright & Co. reiterated coverage of CollPlant Biotechnologies with a rating of Buy and set a new price target of $26.00 from $13.00 previously
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Venture Partner at Flagship Pioneering, as well as the former President, CEO, and Chairman of the Board of Seres Therapeutics Nes-Ziona, Israel, May 23, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV, the "Company"))), a clinical-stage macrophage reprogramming immunotherapy company, today announced the appointment of Roger J. Pomerantz, M.D., FACP, to its Board of Directors as Vice Chairman. Dr. Pomerantz is
- Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov
REHOVOT, Israel, Aug. 19, 2021 /PRNewswire/ -- CollPlant (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, announced the appointment of Alisa Lask to its Board of Directors. Ms. Lask is based in the United States and has held leadership roles in medical aesthetics at both Galderma and Allergan. She will be the seventh independent member of the CollPlant Board. "Alisa brings a strong background in global strategy and marketing that will be very helpful to maximizing the v
6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)
6-K - CollPlant Biotechnologies Ltd (0001631487) (Filer)